Ypsomed has an impressive track record of self-injection devices documenting the long experience in development, filing support and manufacturing of self-injection devices. Amongst the publicly known customers of Ypsomed are Pfizer, Sanofi, Roche/Genentech, Eli Lilly, Merck, GSK, AstraZeneca and many more. Below are just a few examples of Ypsomed’s self-injection milestones:
YpsoMate Zero, 2020
Introduction of YpsoMate Zero the world's first zero carbon emission prefilled autoinjector.
SmartPilot for UnoPen, 2020
Introduction of SmartPilot for UnoPen transforming the dial-and-dose UnoPen into a fully connected system.
First FixPen approval and launch for Teriparatide for treating osteoporosis.
YpsoMate 2.25 for Teva, 2019
Launch of Teva's Ajovy: The world's first approval and launch of a 2.25mL PFS based autoinjector.
Launch of 5 additional YpsoMate 1mL autoinjectors in key markets such as US, EU and JP including Teva's Copaxone and Asahi Kasei's Teribone.
Introduction of the YpsoDose pre-filled and pre-assembled large volume patch injector.
Ypsomed teams up with Philips for the development of its new SmartServices to simplify medication adherence monitoring.
YpsoMate for Terumo, 2018
First YpsoMate 1mL approval and launch for Mylan/FKB's Hulio (adalimumab) for the treatment of chronic autoimmune diseases.
SmartPilot for YpsoMate, 2017
Introduction of SmartPilot for YpsoMate transforming the proven YpsoMate autoinjector into a smart product system.
YpsoMate 2.25 Pro, 2016
Introduction of an autoinjector suitable for 2.25ml syringes and viscous injection volumes up to 2.25ml. A high power constant force spring is capable to inject highly viscous formulations.
YpsoMate 2.25, 2015
Introduction of an autoinjector suitable for the 2.25ml syringe and injection volumes up to 2.25ml.
LyoTwist Trio for AstraZeneca, 2014
Introduction of a customized version of LyoTwist Trio for AstraZeneca’s Bydureon-Pen.
LyoTwist Trio for GSK, 2014
Introduction of a customized version of LyoTwist Trio for GSK’s Tanzeum™/Eperzan®.
Introduction and first launch of the prefilled UnoPen for insulin and other multidose therapies providing a familiar handling experience and high level of patient acceptance.
YpsoPen for Dongbao, 2013
Launch of YpsoPen, the intuitive dial & dose reusable pen, for Dongbao's Sulin insulin
Introduction of a new 2-step “buttonless” autoinjector that sets new standards for simplicity and patient feedback. YpsoMate is currently being used by a number of customers for clinical trials in a range of therapeutic indications.
ServoPen for Dongbao, 2010
The first reusable automatic insulin pen that won the red dot design award, launched first as Gansulin Pen in China and in customized versions in other markets.
OptiSet for Sanofi, 1999
With this new generation of a disposable insulin pen, Ypsomed set a benchmark in the industry.
KabiPen for Kabi Pharmacia (Pfizer), 1989
The world’s first pen for human growth hormone and for dual-chamber cartridges. With this pen Ypsomed built the foundation for pens compatible with dual-chamber cartridges.
OptiPen for Hoechst (Sanofi), 1985
As one of the world’s first insulin pens this pen is considered to be one of the forerunners of all following generations of insulin pens.